Literature DB >> 15099279

A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia.

V E Price1, M Carcao, B Connolly, P Chait, A Daneman, M Temple, A M Stain, L Sung, H Al-Tralbosi, V S Blanchette.   

Abstract

BACKGROUND: Central venous catheters (CVCs) are often inserted into boys with hemophilia to secure venous access for factor prophylaxis and immune tolerance induction therapy. Complications associated with CVCs include catheter-related infections, local hemorrhage, and mechanical failure. Less frequently reported is CVC-related deep venous thrombosis (DVT). We conducted a prospective study to determine the frequency and outcome of this complication.
METHODS: All boys (n = 16) with congenital hemophilia A or B with a CVC in place who were registered in the pediatric comprehensive care program at the Hospital for Sick Children, Toronto, were included in the study. They were prospectively assessed by imaging studies and clinical examinations for CVC-related DVT at two time-points, 2 years apart. Each boy was evaluated for inherited hypercoagulability.
RESULTS: Eleven (69%) of the 16 boys had radiological evidence of DVT at the first evaluation and 13/16 (81%) at the second evaluation. In two boys there was improvement in the venogram findings at the second evaluation. None of the CVC-related DVTs completely resolved. Median age at the time of initial insertion of a CVC was 1.0 years (range 0.02-6.7 years). Median duration of CVC placement was 6.4 years (range 3.3-15.5 years). Only 4/13 boys with DVTs had clinical evidence of upper venous system obstruction. Only one boy, who did not develop a DVT, had a low protein C level.
CONCLUSIONS: CVC-related DVTs occur in the majority of boys with hemophilia who have CVCs inserted for a prolonged period of time. Annual screening with imaging is recommended for boys with CVCs in place for >/= 3 years. Consideration should be given to removing CVCs as soon as peripheral venous access is feasible.

Entities:  

Mesh:

Year:  2004        PMID: 15099279     DOI: 10.1111/j.1538-7836.2004.00653.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

Review 1.  Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

2.  Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: A systematic review.

Authors:  Anjali A Sharathkumar; Tina Biss; Ketan Kulkarni; Sanjay Ahuja; Matt Regan; Christoph Male; Shoshana Revel-Vilk
Journal:  J Thromb Haemost       Date:  2020-04-15       Impact factor: 5.824

Review 3.  Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis.

Authors:  E Vidal; A Sharathkumar; J Glover; E V S Faustino
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

4.  Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Authors:  Gili Kenet; Hervé Chambost; Christoph Male; Thierry Lambert; Susan Halimeh; Tatiana Chernova; Maria Elisa Mancuso; Julie Curtin; Christine Voigt; Yanyan Li; Iris Jacobs; Elena Santagostino
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

Review 5.  Non-factor therapies for bleeding disorders: A primer for the general haematologist.

Authors:  Dawn Swan; Johnny Mahlangu; Jecko Thachil
Journal:  EJHaem       Date:  2022-04-28

6.  Post splenectomy fatal pulmonary embolism in a patient with moderate hemophilia a.

Authors:  Abdolhossein Davoodabadi; Mohammad Mahdi Adib; Behrooz Keleidari
Journal:  Iran J Med Sci       Date:  2011-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.